Green Tea and Quercetin in Combination With Docetaxel Chemotherapy in Castration-resistant Prostate Cancer Patients

Eligibility Criteria

• * Signed and dated informed consent form and HIPPA (Health Insurance Portability and Accountability Act) authorization.
• * Stated willingness to comply with all study procedures and availability for the duration of the study.
• * Male patients 18 years or older
• * Diagnosed with metastatic prostate cancer
• * History of confirmed progressive disease with concurrent use of medical castration (e.g. luteinizing hormone-releasing hormone analogue), or surgical castration
• * Confirmed progressive disease with concurrent use of enzalutamide, apalutamide, darolutamide, and/or abiraterone acetate
• * Clinical decision to start doc infusion with prednisone treatment
• * Adequate bone marrow function (absolute neutrophil count (ANC) more than1500 cells/mm³, platelet count more than 100,000 cells/mm³)
• * Adequate liver function (total bilirubin less than upper limit of normal (ULN), alanine aminotransferase (ALT) less than 1.5 x ULN, aspartate aminotransferase (AST) less than 1.5 x ULN)
• * Adequate renal function (serum creatinine level within normal limits)
• * At least a 6-month or greater life expectancy
• * Willing to stop consuming tea or tea-containing products and quercetin supplements throughout the entire intervention period except for the green tea extract and quercetin provided during study intervention
• * Prior treatment of chemotherapy and/or radiotherapy for metastatic disease
• * Any comorbid condition that would preclude the administration of docetaxel/prednisone
• * Ongoing alcohol abuse
• * Significant medical or psychiatric conditions that would make the patient a poor protocol candidate
• * Prior allergic reaction to tea, tea products or quercetin supplements
• * Allergies to multiple food items or nutritional supplements